Based on the retrospective exploratory research in TOPACIO trial,135 potential predictive biomarkers for the efficacy of the niraparib/pembrolizumab combination are mutational signature 3 and interferon signaling in the CD8+ T cells in the tumor microenvironment, in addition to HR or BRCA mutation status.139. Here, CD8A is linked to neoplasm.